# Optimizing Benefits‐Harms of H. pylori Screen‐and‐Treat Programs Tailored to the Regional Settings

**Authors:** Duco T. Mülder, Yi‐Chia Lee, Mario Dinis‐Ribeiro, Melissa McLeod, Jin Young Park, Iris Lansdorp‐Vogelaar

PMC · DOI: 10.1111/hel.70111 · Helicobacter · 2026-03-04

## TL;DR

This paper explains how decision modeling can help create cost-effective H. pylori screening and treatment programs that are tailored to specific regions.

## Contribution

The paper introduces a framework for using decision modeling to optimize H. pylori screen-and-treat programs based on regional needs.

## Key findings

- Modeling studies show H. pylori screen-and-treat is cost-effective in diverse populations.
- Decision modeling can improve resource allocation and health equity in these programs.
- Integrating H. pylori screening with other preventive programs may enhance efficiency.

## Abstract

This article outlines how decision modeling can be used to optimize the cost‐effectiveness of 
H. pylori
 screen‐and‐treat programs. Decision models enable the translation of data from pilot studies into locally tailored strategies by adapting test modalities, treatment options, and the need to retest specific to the local setting. We summarize existing evidence from modeling studies, which consistently demonstrate that 
H. pylori
 screen‐and‐treat is cost‐effective across diverse populations. In addition, we discuss how decision modeling can support resource allocation, promote health equity, and guide implementation planning. Integrating 
H. pylori
 screen‐and‐treat into established preventive programs, such as colorectal cancer screening, may further increase efficiency and feasibility. The article concludes with a proposed research agenda to advance efficient 
H. pylori
 screen‐and‐treat programs across the globe.

## Full-text entities

- **Genes:** CagA [NCBI Gene 48200769]
- **Diseases:** Cancer (MESH:D009369), cervical cancer (MESH:D002583), H. pylori (MESH:D016481), anaphylaxis (MESH:D000707), Gastric Cancer (MESH:D013274), infection (MESH:D007239), peptic ulcer disease (MESH:D010437), upper and lower gastrointestinal lesions (MESH:D005767), gastric lymphoma (MESH:D018442), digestive tract diseases (MESH:D004066), Health Disparities (MESH:D011019), stage I-II disease (MESH:D058625), deaths (MESH:D003643), CRC (MESH:D015179), dyspepsia (MESH:D004415), infectious disease (MESH:D003141), breast cancer (MESH:D001943)
- **Chemicals:** 13C- (MESH:C000615229), 13C-UBT (-)
- **Species:** Human papillomavirus (species) [taxon 10566], hepatitis C virus [taxon 11103], Hepatitis B virus (no rank) [taxon 10407], Helicobacter pylori (species) [taxon 210], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12960071/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12960071/full.md

## References

57 references — full list in the complete paper: https://tomesphere.com/paper/PMC12960071/full.md

---
Source: https://tomesphere.com/paper/PMC12960071